Benimetskaya L - Search Results

1

Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.

Benimetskaya L, Ayyanar K, Kornblum N, Castanotto D, Rossi J, Wu S, Lai J, Brown BD, Popova N, Miller P, McMicken H, Chen Y, Stein CA. Benimetskaya L, et al. Clin Cancer Res. 2006 Aug 15;12(16):4940-8. doi: 10.1158/1078-0432.CCR-06-1002. Clin Cancer Res. 2006. PMID: 16914583

2

Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.

Vilenchik M, Raffo AJ, Benimetskaya L, Shames D, Stein CA. Vilenchik M, et al. Among authors: benimetskaya l. Cancer Res. 2002 Apr 1;62(7):2175-83. Cancer Res. 2002. PMID: 11929841

3

Antisense therapy: recent advances and relevance to prostate cancer.

Benimetskaya L, Stein CA. Benimetskaya L, et al. Clin Prostate Cancer. 2002 Jun;1(1):20-30. doi: 10.3816/cgc.2002.n.003. Clin Prostate Cancer. 2002. PMID: 15046709 Review.

4

Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen).

Raffo A, Lai JC, Stein CA, Miller P, Scaringe S, Khvorova A, Benimetskaya L. Raffo A, et al. Among authors: benimetskaya l. Clin Cancer Res. 2004 May 1;10(9):3195-206. doi: 10.1158/1078-0432.ccr-03-0287. Clin Cancer Res. 2004. PMID: 15131061

5

Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma.

Benimetskaya L, Wittenberger T, Stein CA, Hofmann HP, Weller C, Lai JC, Miller P, Gekeler V. Benimetskaya L, et al. Clin Cancer Res. 2004 Jun 1;10(11):3678-88. doi: 10.1158/1078-0432.CCR-03-0569. Clin Cancer Res. 2004. PMID: 15173074

6

Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.

Benimetskaya L, Lai JC, Khvorova A, Wu S, Hua E, Miller P, Zhang LM, Stein CA. Benimetskaya L, et al. Clin Cancer Res. 2004 Dec 15;10(24):8371-9. doi: 10.1158/1078-0432.CCR-04-1294. Clin Cancer Res. 2004. PMID: 15623615

7

Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells.

Lai JC, Benimetskaya L, Khvorova A, Wu S, Hua E, Miller P, Stein CA. Lai JC, et al. Among authors: benimetskaya l. Mol Cancer Ther. 2005 Feb;4(2):305-15. Mol Cancer Ther. 2005. PMID: 15713901

8

518A2 melanoma cells are protected by G3139 and other antineoplastic agents against the cytotoxic effects of DTIC.

Benimetskaya L, Miller P, Stein CA. Benimetskaya L, et al. Oligonucleotides. 2005 Fall;15(3):206-14. doi: 10.1089/oli.2005.15.206. Oligonucleotides. 2005. PMID: 16201908

9

Antisense strategies for oncogene inactivation.

Stein CA, Benimetskaya L, Mani S. Stein CA, et al. Among authors: benimetskaya l. Semin Oncol. 2005 Dec;32(6):563-72. doi: 10.1053/j.seminoncol.2005.09.003. Semin Oncol. 2005. PMID: 16338422 Review.

10

Induction of apoptosis by G3139 in melanoma cells.

Benimetskaya L, Lai JC, Khvorova A, Wu S, Miller P, Stein CA. Benimetskaya L, et al. Ann N Y Acad Sci. 2005 Nov;1058:235-45. doi: 10.1196/annals.1359.033. Ann N Y Acad Sci. 2005. PMID: 16394140 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters